WATERTOWN, Mass., Sept. 1, 2026
Kymera Therapeutics, Inc. has announced upcoming presentations featuring clinical data for KT-621, its first-in-class oral STAT6 degrader, at the European Respiratory Society (ERS) Congress in Barcelona and the European Academy of Dermatology & Venereology (EADV) Congress in Vienna. The company will present previously reported Phase 1b data evaluating KT-621 in patients with moderate-to-severe atopic dermatitis (AD). The presentations will highlight clinical activity across Type 2 inflammatory diseases, including outcomes in patients with AD and comorbid asthma or allergic rhinitis, as well as improvements in pruritus and sleep. The company has also completed enrollment in the BROADEN2 Phase 2b trial in AD, with topline results expected by the end of 2026 and Phase 3 trials planned to begin by mid-2027.
KT-621 Data to Be Presented at European Congresses
Kymera Therapeutics will present two KT-621 posters at major European medical congresses in September and October 2026. At the ERS Congress, scheduled for September 5-9 in Barcelona, the company will present Phase 1b data examining KT-621 in patients with moderate-to-severe AD who also have asthma or allergic rhinitis. The presentation is scheduled for September 8 and will focus on safety and evidence of clinical activity across Type 2 inflammatory diseases. At the EADV Congress in Vienna, scheduled for September 30 to October 3, Kymera will present Phase 1b results focused on pruritus and sleep outcomes in patients with moderate-to-severe AD. The presentations provide additional visibility into the clinical profile of KT-621 as the program advances through mid-stage development.
Phase 2b AD Enrollment Completed
Enrollment has been completed in Kymera’s BROADEN2 Phase 2b trial in atopic dermatitis, representing an important development milestone for KT-621. The company expects to report topline Phase 2b data by year-end 2026 and plans to initiate Phase 3 AD trials by mid-2027, subject to the development program. In parallel, KT-621 is being evaluated in the BREADTH Phase 2b asthma trial, with topline data expected in late 2027. The parallel development strategy allows Kymera to evaluate the oral degrader across two major Type 2 inflammatory diseases while building a broader clinical development package for the candidate.
Advertisement
Oral STAT6 Degradation Targets Type 2 Inflammation
KT-621 is an investigational once-daily oral STAT6 degrader designed to directly target STAT6, a transcription factor involved in IL-4 and IL-13 signaling and a central driver of Type 2 inflammation. In the Phase 1b AD study, Kymera reported deep STAT6 degradation in blood and skin, reductions in disease-related Type 2 inflammatory biomarkers and improvements in clinical and patient-reported outcomes. The company also reported a favorable safety and tolerability profile. KT-621 is currently being evaluated in atopic dermatitis and asthma, with potential applications across additional Type 2 inflammatory diseases. The candidate’s progression into Phase 2b development, completion of AD enrollment and planned Phase 3 program represent the next major stages in Kymera’s effort to establish oral targeted protein degradation as a potential treatment approach for inflammatory diseases..
Source:Kymera Therapeutics,, press relese
